A Randomized, Double‐Blind, Parallel‐Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects-Reference-Cited by-同舟云学术

A Randomized, Double‐Blind, Parallel‐Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects

Published:2020-05-28 Issue:3 Volume:10 Page:317-325
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Cao Guoying¹,Yu Jicheng¹,Wu Jufang¹,Wang Jingjing¹,Xue Yu¹,Yang Xiaoli¹,Zhang Jing¹

Affiliation:

1. Phase I Clinical Trial Center Huashan Hospital Fudan University Shanghai China

Funder

Major New Drugs Innovation and Development

Science Program of Zhejiang province, China

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.816

Reference21 articles.

1. Update upon efficacy and safety of TNF-α inhibitors

2. Adalimumab for the treatment of immune-mediated diseases: An update on old and recent indications

3. Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis

4. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future

5. Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biosimilar monoclonal antibodies in China: A patent review;Bioengineered;2022-06-01

2. Phase I, randomized, double-blind, single-dose study to assess the pharmacokinetics, safety, and immunogenicity of the proposed biosimilar SCT630 and adalimumab in healthy Chinese subjects;International Immunopharmacology;2022-05

3. Comparative assessment of pharmacokinetic parameters between HS016, an adalimumab biosimilar, and adalimumab (Humira®) in healthy subjects and ankylosing spondylitis patients: Population pharmacokinetic modeling;Advances in Clinical and Experimental Medicine;2022-02-11

4. Physicochemical and Functional Characterization of HS016, a Biosimilar of Adalimumab (Humira);Journal of Pharmaceutical Sciences;2021-12

5. A randomized, double-blind, single-dose, two-way, parallel phase I clinical study comparing the pharmacokinetics and safety of adalimumab injecta and Humira® in healthy Chinese male volunteers;Expert Opinion on Biological Therapy;2021-06-16